Synairgen (SNG) ORD GBP 0.01
- Add to watchlist
- Create an alert
- This stock can be held in a
4.11p
4.75p
10.62p
£8.27 million
4.11p
3.83p
3.00p
n/a
0.36p (9.47%) Previous:
0.36p
170,049
n/a
75,000
Performance
1 week 1W | 14.03% | 1 year 1Y | 45.56% |
---|---|---|---|
1 month 1M | 4.72% | 2 years 2Y | 78.39% |
3 months 3M | 16.99% | 3 years 3Y | 97.3% |
6 months 6M | 15.88% | 5 years 5Y | 54.39% |
Performance figures are based on the previous close price. Past performance is not an indication of future performance.
Fundamental data
Year ending: | 31/12/2023 | 31/12/2022 |
---|---|---|
Revenue (£m) | n/a | n/a |
Profit before tax (£m) | (9.66) | (20.09) |
Adjusted EPS (p): | (4.18) | (8.76) |
P/E ratio | n/a | n/a |
PEG | n/a | n/a |
EPS growth (%) | n/a | n/a |
Values are quoted in the stock's local currency: British pound
All fundamental dataDividend information for this stock is not available.
Dividend information for this stock is not available.
Ready to invest?
Important Documents
There are no documents available for this stock.
-
Synairgen names Joseph Colliver as CFO
11 October 2023 10:26
-
Synairgen posts positive results for phase 2 trial with SNG001 against Covid-19
4 October 2022 08:00
-
Synairgen unveils positive clinical trial data
7 September 2022 07:59
-
Interim Results
26 September 2024 07:00
-
Appointment of New Chairman and Notice of AGM
18 September 2024 07:00
-
Board Change
5 September 2024 07:00
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.